KR101833465B1 - 항신경 성장 인자 항체 및 그의 제조방법과 이용방법 - Google Patents

항신경 성장 인자 항체 및 그의 제조방법과 이용방법 Download PDF

Info

Publication number
KR101833465B1
KR101833465B1 KR1020137032545A KR20137032545A KR101833465B1 KR 101833465 B1 KR101833465 B1 KR 101833465B1 KR 1020137032545 A KR1020137032545 A KR 1020137032545A KR 20137032545 A KR20137032545 A KR 20137032545A KR 101833465 B1 KR101833465 B1 KR 101833465B1
Authority
KR
South Korea
Prior art keywords
delete delete
amino acid
antibody
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137032545A
Other languages
English (en)
Korean (ko)
Other versions
KR20140041532A (ko
Inventor
데이비드 기어링
Original Assignee
넥스베트 오스트레일리아 피티와이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 넥스베트 오스트레일리아 피티와이 리미티드 filed Critical 넥스베트 오스트레일리아 피티와이 리미티드
Publication of KR20140041532A publication Critical patent/KR20140041532A/ko
Application granted granted Critical
Publication of KR101833465B1 publication Critical patent/KR101833465B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020137032545A 2011-05-06 2012-05-08 항신경 성장 인자 항체 및 그의 제조방법과 이용방법 Active KR101833465B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161483491P 2011-05-06 2011-05-06
US61/483,491 2011-05-06
US201161531439P 2011-09-06 2011-09-06
US61/531,439 2011-09-06
PCT/GB2012/051004 WO2012153123A1 (en) 2011-05-06 2012-05-08 Anti-nerve growth factor antibodies and methods of preparing and using the same

Publications (2)

Publication Number Publication Date
KR20140041532A KR20140041532A (ko) 2014-04-04
KR101833465B1 true KR101833465B1 (ko) 2018-02-28

Family

ID=46168541

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137032545A Active KR101833465B1 (ko) 2011-05-06 2012-05-08 항신경 성장 인자 항체 및 그의 제조방법과 이용방법

Country Status (14)

Country Link
US (2) US20140170136A1 (enExample)
EP (2) EP3502136A1 (enExample)
JP (2) JP6181043B2 (enExample)
KR (1) KR101833465B1 (enExample)
CN (1) CN103764677A (enExample)
AU (1) AU2012252153B2 (enExample)
BR (1) BR112013028652A8 (enExample)
CA (1) CA2834983C (enExample)
ES (1) ES2704007T3 (enExample)
GB (1) GB2504888B (enExample)
MY (1) MY160884A (enExample)
RU (1) RU2640252C2 (enExample)
SG (2) SG10201500957QA (enExample)
WO (1) WO2012153123A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
WO2012075340A2 (en) 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
AU2012252153B2 (en) * 2011-05-06 2016-07-07 Zoetis Services Llc Anti-nerve growth factor antibodies and methods of preparing and using the same
CA2932515C (en) 2013-12-20 2023-08-01 Intervet International B.V. Caninized antibodies
ES2853823T3 (es) 2014-09-30 2021-09-17 Intervet Int Bv Anticuerpos de PD-L1 que se unen a PD-L1 canino
CN104910274B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体12c11及其杂交瘤细胞株
CN104774265B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体11f1及其杂交瘤细胞株
BR112017025029A2 (pt) * 2015-05-22 2018-08-07 Astellas Pharma Inc. ?novo fragmento fab de anticorpo ngf anti- humano?.
JP7008020B2 (ja) 2015-12-18 2022-01-25 インターベット インターナショナル ベー． フェー． ヒトおよびイヌｉｌ－４ｒアルファに対するイヌ化ヒト抗体
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
CN119390821A (zh) 2017-08-15 2025-02-07 伊兰科美国公司 兽药用IgG Fc变体
GB2578867A (en) * 2018-10-09 2020-06-03 Genome Res Ltd Animal models and therapeutic molecules
AU2019250128A1 (en) 2018-10-15 2020-04-30 Avent Inc. Compositions, systems, kits, and methods for neural ablation
CA3199234A1 (en) * 2020-10-22 2022-04-28 Scout Bio, Inc. Method of suppressing immune response to vector-delivered therapeutic protein
TW202306990A (zh) 2021-05-12 2023-02-16 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｒａｎｋｌ和ｎｇｆ的抗原結合分子及其醫藥用途
KR20240107201A (ko) 2021-08-31 2024-07-08 스카우트 바이오, 인코포레이티드 항원-결합 분자 및 이의 용도
WO2025036564A1 (de) * 2023-08-17 2025-02-20 Gottfried Wilhelm Leibniz Universität Hannover (Luh) Nukleinsäuresequenz, vektor, screening-verfahren und verfahren zur herstellung von rekombinanten antikörpern

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061540A2 (en) * 2003-12-24 2005-07-07 Lay Line Genomics S.P.A. Method for the humanization of antibodies and humanized antibodies thereby obtained
WO2010128398A1 (en) 2009-05-04 2010-11-11 Pangenetics 110 B.V. Antibodies against nerve growth factor (ngf) with enhanced in vivo stability

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
AU632843B2 (en) * 1989-08-10 1993-01-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
EP3372614B1 (en) * 2004-04-07 2022-06-08 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
US20070212703A1 (en) 2005-09-27 2007-09-13 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
US8337842B2 (en) * 2008-09-04 2012-12-25 Vet Therapeutics, Inc. Monoclonal antibodies
BR112012022342A2 (pt) * 2010-03-04 2017-02-14 Vet Therapeutics Inc anticorpos monoclonais dirigidos a cd52
JP5911813B2 (ja) * 2010-03-04 2016-04-27 ベット・セラピューティクス・インコーポレイテッドＶｅｔ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Ｃｄ２０に対するモノクローナル抗体
CA2808577C (en) * 2010-08-19 2018-09-25 Abbott Laboratories Anti-ngf antibodies and their use
AU2012252153B2 (en) * 2011-05-06 2016-07-07 Zoetis Services Llc Anti-nerve growth factor antibodies and methods of preparing and using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061540A2 (en) * 2003-12-24 2005-07-07 Lay Line Genomics S.P.A. Method for the humanization of antibodies and humanized antibodies thereby obtained
WO2010128398A1 (en) 2009-05-04 2010-11-11 Pangenetics 110 B.V. Antibodies against nerve growth factor (ngf) with enhanced in vivo stability

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Mol. Immunol. 43(8): 1243-1257(2005.08.22. 인터넷 공지)
Vet. Immunol. Immunopathol. 110(3-4): 363-367(2006.02.09.)

Also Published As

Publication number Publication date
MY160884A (en) 2017-03-31
AU2012252153A1 (en) 2013-11-14
RU2640252C2 (ru) 2017-12-27
EP2705056B1 (en) 2018-11-14
CN103764677A (zh) 2014-04-30
NZ617448A (en) 2015-01-30
WO2012153123A1 (en) 2012-11-15
JP6181043B2 (ja) 2017-08-16
BR112013028652A8 (pt) 2017-12-26
SG10201500957QA (en) 2015-04-29
GB201320050D0 (en) 2013-12-25
GB2504888B (en) 2016-02-03
RU2013154307A (ru) 2015-06-20
KR20140041532A (ko) 2014-04-04
EP3502136A1 (en) 2019-06-26
BR112013028652A2 (pt) 2016-11-29
GB2504888A (en) 2014-02-12
EP2705056A1 (en) 2014-03-12
ES2704007T3 (es) 2019-03-13
JP2017123870A (ja) 2017-07-20
SG194795A1 (en) 2013-12-30
CA2834983C (en) 2020-11-17
AU2012252153A8 (en) 2013-12-19
AU2012252153B2 (en) 2016-07-07
CA2834983A1 (en) 2012-11-15
JP6526089B2 (ja) 2019-06-05
US20190276525A1 (en) 2019-09-12
JP2014519318A (ja) 2014-08-14
US20140170136A1 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
KR101833465B1 (ko) 항신경 성장 인자 항체 및 그의 제조방법과 이용방법
KR101783398B1 (ko) 항신경성 성장인자 항체 및 그의 제조방법과 이용방법
KR101783929B1 (ko) 항신경성 성장 인자 항체 및 그의 제조방법과 이용방법
CA2835094C (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
US20140294815A1 (en) Caninised tumour necrosis factor antibodies and methods of using the same
EP4026845A1 (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
HK1195570B (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
HK1195570A (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
HK1195781A (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
HK1195781B (en) Anti-nerve growth factor antibodies and methods of preparing and using the same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131206

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160216

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20160216

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20160824

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161123

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170407

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20161123

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20160615

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170407

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160913

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20160216

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170601

Patent event code: PE09021S01D

PX0701 Decision of registration after re-examination

Patent event date: 20171010

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20170502

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20170407

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20160913

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20160216

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180222

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180223

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20211229

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20221221

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20240102

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20241223

Start annual number: 8

End annual number: 8